Pulse Biosciences (PLSE) Earnings Date & Reports

Key Takeaways

• Pulse Biosciences reported third-quarter 2026 revenue of $0.4 million, below the consensus estimate of roughly $0.52 million but up from $0.1 million a year earlier.
• GAAP net loss widened to $23.1 million, or $0.32 per share, versus a consensus loss of $0.29 per share and a $19.4 million loss in the prior-year quarter.
• The company completed enrollment in its NANOPULSE-AF U.S. pivotal study roughly three months ahead of schedule, a key clinical milestone for its cardiac ablation platform.
• Cash, cash equivalents, and marketable securities climbed to $189.2 million, supported by $95.8 million in net proceeds raised through at-the-market (ATM) offerings during the quarter.
• Investor focus remains on regulatory submissions and clinical data readouts rather than near-term revenue, which is still limited to a controlled commercial launch.
• You can find more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to discover AI-driven trading strategies and market insights.

Earnings Context and Why It Matters

Pulse Biosciences (NASDAQ: PLSE) is a clinical-stage medical technology company developing a proprietary Nanosecond Pulsed Field Ablation (nsPFA) platform used to non-thermally ablate targeted cells while sparing surrounding tissue. Its primary focus is the treatment of atrial fibrillation (AF), a common heart rhythm disorder. Because the company is still in the pre-commercial phase for its cardiac products, quarterly financial figures matter less than clinical progress, regulatory milestones, and balance-sheet strength. The third-quarter report therefore carried outsized weight as investors looked for confirmation that the NANOPULSE-AF pivotal trial remained on track and that the company had sufficient capital to fund the path toward regulatory approval and a potential commercial launch.

Reported Results

For the third quarter ended September 30, 2026, Pulse Biosciences reported total revenue of $0.4 million ($395,000), below the consensus estimate of roughly $0.52 million but up from $86,000 in the year-ago quarter. The revenue reflects continued case volume within the controlled launch of its Vybrance dermatology system.

The company posted a GAAP (Generally Accepted Accounting Principles) net loss of $23.1 million, or $0.32 per share, wider than the $0.29 per share consensus loss and the $19.4 million net loss reported a year earlier. Non-GAAP net loss, which excludes certain non-cash and non-recurring items, was $17.5 million, up from $13.5 million in the prior-year period, reflecting higher clinical program investment and employee-related costs.

Cash, cash equivalents, and marketable securities ended the quarter at $189.2 million, up from $101.6 million as of June 30, 2026. The company raised $95.8 million in net proceeds through its at-the-market (ATM) equity programs during the quarter, with roughly $64 million of ATM capacity remaining.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following clinical-stage medical technology names like Pulse Biosciences, the AI Screener offers a structured way to surface comparable opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around Pulse Biosciences was driven less by financial results and more by clinical execution. The company entered the quarter having already accelerated enrollment in its NANOPULSE-AF U.S. pivotal study, and management had signaled strong physician enthusiasm for the nPulse catheter. The completed enrollment, three months ahead of the original timeline, reinforced that narrative even as the bottom line widened.

For a pre-revenue medical device company, a modest revenue miss and a slightly wider-than-expected loss are generally viewed through the lens of clinical milestones and cash runway. The balance-sheet strengthening and on-track regulatory timelines gave investors reason to weigh the near-term loss against longer-term commercial potential, though the continued cash burn and reliance on capital markets remain key risk factors that shape sentiment.

Forward Outlook and Key Factors to Monitor

With NANOPULSE-AF fully enrolled, management's focus now shifts to pre-commercial readiness and regulatory submissions. The company is advancing modular submissions toward a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA), while also working toward a CE Mark in Europe, which management anticipates in the fourth quarter of 2027.

Investors should watch several catalysts. First, final patient data from the pivotal study is expected to become available in the third quarter of 2027, blending 6-month and 12-month follow-up results that will anchor the PMA submission. Second, the company plans to submit an Investigational Device Exemption (IDE) application for a persistent atrial fibrillation study in the fourth quarter of 2026, expanding the platform into a larger patient population.

Cost trends will also matter. Total GAAP costs and expenses rose to $24.7 million from $20.5 million a year earlier as the company runs multiple trials simultaneously, and management expects spending to increase further as it builds manufacturing capacity and approaches launch readiness. Meanwhile, the NANOCLAMP-AF surgical study remains on track to complete enrollment by the end of the first half of 2027.

Finally, capital deployment remains a central variable. The company ended the quarter with $189.2 million in cash and marketable securities, providing runway for ongoing trials and prelaunch investment, but continued clinical and commercialization spending will determine whether additional financing is needed before revenue scales.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations